IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
Key Highlights
- ➤IMDELLTRA plus IMFINZI cut death risk 58% versus IMFINZI alone
- ➤Median overall survival reached 21.1 months versus 12.7 months
- ➤One-year survival approached 80% versus 53% with IMFINZI alone
- ➤Progression-free survival reached 7.4 months versus 1.9 months
- ➤DeLLphi-304 showed IMDELLTRA extended survival to 13.6 months versus 8.4 months
Expert Statements
Jay Bradner, M.D., Executive Vice President, Research and Development, Artificial Intelligence and Data at Amgen
“These results represent an unprecedented advance for patients with extensive-stage small cell lung cancer, demonstrating a magnitude of survival benefit rarely seen in this aggressive disease”
Jay Bradner, M.D., Executive Vice President, Research and Development, Artificial Intelligence and Data at Amgen
“Extending median overall survival beyond 21 months while reducing the risk of death by 58% reinforces the potential to revolutionize the standard of survival and redefine expectations for patients by introducing IMDELLTRA earlier in the course of treatment.”
Jay Bradner, M.D., Executive Vice President, Research and Development, Artificial Intelligence and Data at Amgen
“These findings underscore our ambition to fundamentally change the trajectory of small cell lung cancer, and we are moving with urgency to share these results with regulatory authorities worldwide.”
Jacob Sands, M.D., Associate Chief of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute
“For a disease where durable survival has remained extremely difficult to achieve, the magnitude and consistency of benefit in DeLLphi-305 are striking,”
Jacob Sands, M.D., Associate Chief of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute
“Importantly, the benefit was seen across clinically relevant groups, including patients with brain metastases.”
Jacob Sands, M.D., Associate Chief of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute
“Today's remarkable results demonstrate substantial progress in our work to achieve meaningfully longer disease control and survival for patients with extensive-stage small cell lung cancer, further highlighting the importance of effective treatment at the earliest possible opportunity.”
Andrea Ferris, MBA, President and CEO of LUNGevity Foundation
“For too long, patients with small cell lung cancer have had too few treatment advances and too little time,”
Andrea Ferris, MBA, President and CEO of LUNGevity Foundation
“For the patients we serve, today's results represent not only the potential to substantially improve outcomes for patients before they progress on first-line treatment, but also a tangible source of hope – hope for more life milestones, more moments of joy, and, ultimately, more time.”
IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER PR Newswire
Nearly 80% of Patients Were Alive at One Year Versus 53% with IMFINZI Alone and Progression-Free Survival More Than Tripled
Get started
Create a free account to read the full story.